Relation between reduction in fractional exhaled nitric oxide and efficacy in asthma patients treated with dupilumab
I. Pavord (Oxford (Oxfordshire), United Kingdom), Y. Deniz (Tarrytown, NY, United States), T. Casale (Tampa, FL, United States), J. Corren (Los Angeles, CA, United States), M. Fitzgerald (Vancouver, BC, Canada), N. Daizadeh (Cambridge, MA, United States), A. Jagerschmidt (Chilly-Mazarin, France), M. Dillon (Tarrytown, NY, United States), R. Gall (Tarrytown, NY, United States), N. Pandit-Abid (Bridjewater, NJ, United States), S. Siddiqui (Tarrytown, NY, United States), J. Jacob-Nara (Bridjewater, NJ, United States), P. Rowe (Bridjewater, NJ, United States), W. Busse (Madison, WI, United States)
Source: International Congress 2022 – Recent advances in biological treatments for asthma
Session: Recent advances in biological treatments for asthma
Session type: Oral Presentation
Number: 3675
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Pavord (Oxford (Oxfordshire), United Kingdom), Y. Deniz (Tarrytown, NY, United States), T. Casale (Tampa, FL, United States), J. Corren (Los Angeles, CA, United States), M. Fitzgerald (Vancouver, BC, Canada), N. Daizadeh (Cambridge, MA, United States), A. Jagerschmidt (Chilly-Mazarin, France), M. Dillon (Tarrytown, NY, United States), R. Gall (Tarrytown, NY, United States), N. Pandit-Abid (Bridjewater, NJ, United States), S. Siddiqui (Tarrytown, NY, United States), J. Jacob-Nara (Bridjewater, NJ, United States), P. Rowe (Bridjewater, NJ, United States), W. Busse (Madison, WI, United States). Relation between reduction in fractional exhaled nitric oxide and efficacy in asthma patients treated with dupilumab. 3675
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|